Ayogo’s behavioral support platform creates value for innovative medical device and life sciences companies by helping patients successfully transition on to therapy. The company’s “dynamic tailoring” technology ensures patients receive personal, relevant, and timely support based on each patient’s unique psychosocial context.
All investors in the Ayogo’s Series A financing round participated in this new financing, including Merck Global Health Innovation Fund, 7Wire Ventures, and Excel Venture Management. New investors in the round include Baxter International Inc. and MEDTEQ, the pan-Canadian Consortium for Industrial Research and Innovation in Medical Technology.
“We are delighted to be working with investment partners that understand the potential our products have to improve health outcomes while reducing costs, and to positively impact the lives of patients, families, and clinicians,” CEO Michael Fergusson shared regarding the announcement.
“In this challenging time it is both a great honor and responsibility to have received the capital to help grow and accelerate our mission and business, and we intend to maintain our focus on leveraging advanced technology and cutting-edge behavioral science to improve the human condition.”
Ayogo was founded in 2011 by Michael Fergusson and Paul Prescod.